pharmaphorum1d
FDA starts review of Sanofi's MS hope tolebrutinib
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
pharmaphorum5d
Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition
Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. The French pharma said it will pay $100 per share in cash for San ...
Hosted on MSN11mon
Sanofi succeeds in late-stage trial for blood disorder candidate
The French drugmaker added rilzabrutinib to its pipeline with its $3.7B acquisition of Principia Biopharma in 2020. Sanofi (NASDAQ:SNY) announced Tuesday that rilzabrutinib, an oral therapy for an ...
Hosted on MSN1mon
Alumis draws Outperform at Oppenheimer on valuation disconnect
whom he said has previously led Principia Biopharma. A drug developer focused on immune-mediated diseases, Principia was acquired by Sanofi (SNY) in 2020 for $3.7B. As for the pipeline ...